HER2 Testing in Metastatic Solid Tumors Beyond Breast and Gastric: Navigating an Evolving Landscape-UNBRANDED ONCOLOGY HER2 Solid Tumor FSP Webinar 2026 Recording

UNBRANDED ONCOLOGY HER2 Solid Tumor FSP Webinar 2026 Recording_PP-US-8201a-2960-1

Video Transcription

Video Summary

The conference introduced an evidence-based review of HER2 testing in metastatic solid tumors beyond the familiar breast and gastric settings. Dr. Michelle Sheeler explained that HER2 overexpression and other ERBB2 alterations are seen across multiple cancers, including bladder/urothelial, biliary tract, endometrial, lung, colorectal, ovarian, cervical, and salivary gland tumors. She emphasized that HER2 can be assessed through three main alteration types: protein overexpression by IHC, gene amplification by ISH or NGS, and activating ERBB2 mutations by NGS.  <br /><br />A major focus was on testing guidelines and scoring systems. Dr. Sheeler reviewed how gastric HER2 IHC criteria are often applied across tumor types, while breast criteria differ by requiring circumferential staining. She also highlighted tumor-specific thresholds, including colorectal and gynecologic cancers, and noted that lung cancer requires separate attention for ERBB2 mutations.  <br /><br />Key reporting points included documenting percentage of positive cells, staining intensity, and membrane pattern, as well as considering pre-analytic factors, specimen type, and assay validation. She stressed that HER2 IHC should be interpreted independently of NGS results. The talk concluded with practical resources, including CAP reporting templates and the HER2Know website, to help pathologists stay current in this evolving landscape.

Keywords

HER2 testing

ERBB2 alterations

metastatic solid tumors

immunohistochemistry (IHC)

gene amplification

NGS mutation analysis

pathology reporting guidelines